- Acquired
Advanced Vision Science, Inc. (AVS), securing scalable commercial intraocular lens (IOL) manufacturing capacity for its Phase 3 lead product candidate the Bimatoprost Drug Pad-IOL System (BIM-IOL System) and accelerating premium IOL portfolio expansion capability. - Announced groundbreaking four-year first-in-human (FIH) efficacy and safety follow-up data of the BIM-IOL System, with a 37% reduction in mean intraocular pressure (IOP) across all dose levels and 86% of patients remaining off all topical IOP-lowering drops.
- Enrollment remains on track in the registrational Phase 3 trials of the BIM-IOL System, with completion expected in 2027.
- Announces completion of first implantations in the FIH study of the Bimatoprost-Drug Ring System (BIM-DRS), a non-IOL-based sustained drug delivery system for glaucoma designed to deliver up to seven years of bimatoprost.
- Cash, cash equivalents and short-term investments of
$215.8 million onSeptember 30, 2026 , are expected to fund planned operations through 2028.
“SpyGlass Pharma continued to execute our objectives over the course of the quarter as we aim to alter the treatment paradigm for glaucoma patients. Our underlying sustained drug delivery platform delivered four years of safety and efficacy results in the FIH trial of the BIM-IOL System, demonstrating that it can control IOP with unprecedented durability. In parallel, enrollment in our Phase 3 trials of the BIM-IOL System remains on track, and we have secured long-term commercial manufacturing supply of the IOL for the BIM-IOL System and have become a supplier of other world-class IOLs,” stated
Corporate Highlights
Acquisition of
Announced Four-Year BIM-IOL FIH Efficacy and Safety Follow-Up Data. In October,
Presentation of Detailed Phase 1/2 Data from the BIM-IOL System Clinical Program at the
Completed First Implantations of the BIM-DRS in FIH Trial. In October,
Third Quarter 2026 Financial Results
Cash, Cash Equivalents and Short-Term Investments totaled
Research and Development Expenses were
General and Administrative Expenses were
Net Loss was
About the Bimatoprost Drug Pad-IOL System
SpyGlass Pharma’s lead product candidate, the BIM-IOL System, comprising novel, proprietary non-bioerodible drug pads attached to its intraocular lens, was designed to be implanted during routine cataract surgery to reduce elevated IOP in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT). The BIM-IOL System being evaluated in ongoing Phase 3 clinical trials is designed to consistently deliver three years of bimatoprost, a prostaglandin analog approved for topical use by the
About the Bimatoprost-Drug Ring System
BIM-DRS is a novel, non-bioerodible, non-IOL-based, sustained-release implant, designed to consistently deliver up to seven years of bimatoprost. BIM-DRS is implanted in a standalone procedure in the ciliary sulcus space, offering extended care for pseudophakic eyes with OAG or OHT and enabling retreatment of patients who have previously received the BIM-IOL System. BIM-DRS is engineered to be a removable and replaceable system, potentially allowing for continuous care over a patient’s lifetime.
About SpyGlass Pharma
SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The Company’s mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.
The SpyGlass Pharma platform, a novel, non-bioerodible drug delivery technology, is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye.
The Company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to solve the lack of ophthalmic innovations that capitalize on durable treatment options. The SpyGlass Pharma platform was originally developed in the Sue Anschutz-Rodgers Eye Center at the University of Colorado Anschutz School of Medicine.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The terms "lasting," "long-term," and "enduring" refer to being able to control IOP for years with one procedure compared to current eye drops, which require dosing daily or even more frequently. All statements in this press release that are not purely historical are forward-looking statements, including, but not limited to, statements regarding: the potential benefits and impact of SpyGlass Pharma’s portfolio on patients, including the potential to provide lasting IOP reduction, anticipated presentation of additional data, SpyGlass Pharma’s plans relating to the Phase 3 clinical development of the BIM-IOL System toward enrollment completion and clinical development of BIM-DRS, the anticipated benefits of SpyGlass Pharma’s acquisition of AVS; and the potential commercial launch and market adoption of the BIM-IOL System after FDA approval. The forward-looking statements contained herein are based upon SpyGlass Pharma’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including those set forth in the Risk Factors section of the Company’s Quarterly Report on Form 10-Q for the three and nine month period ended September 30, 2026 expected to be filed with the Securities and Exchange Commission on November 12, 2026, and in similar disclosures set forth in the other documents that SpyGlass Pharma has filed and may file from time to time with the SEC. These forward-looking statements are made as of the date of this press release, and SpyGlass Pharma assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. SpyGlass Pharma’s views in these forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Media Contact:
Nami Surendranath
+1 (402) 507-6757
nami.surendranath@omc.com
Investor Contact:
Ami Bavishi or Nick Colangelo
Gilmartin Group LLC
investors@spyglasspharma.com
| Condensed Balance Sheets | |||||||||||||||
| (in thousands, except share and per share data) | |||||||||||||||
| (unaudited) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Operating expenses | |||||||||||||||
| Research and development | $ | 10,034 | $ | 8,093 | $ | 29,518 | $ | 21,478 | |||||||
| General and administrative | 16,211 | 3,008 | 34,103 | 6,343 | |||||||||||
| Total operating expenses | 26,245 | 11,101 | 63,621 | 27,821 | |||||||||||
| Loss from operations | (26,245 | ) | (11,101 | ) | (63,621 | ) | (27,821 | ) | |||||||
| Other income | |||||||||||||||
| Interest income | 1,992 | 1,285 | 5,686 | 2,033 | |||||||||||
| Change in fair value of redeemable convertible preferred stock tranche liability | - | - | - | (1,526 | ) | ||||||||||
| Total other income | 1,992 | 1,285 | 5,686 | 507 | |||||||||||
| Loss before income tax | (24,253 | ) | (9,816 | ) | (57,935 | ) | (27,314 | ) | |||||||
| Income tax provision | - | - | - | - | |||||||||||
| Net loss and comprehensive loss | $ | (24,253 | ) | $ | (9,816 | ) | $ | (57,935 | ) | $ | (27,314 | ) | |||
| Net loss per share | |||||||||||||||
| Weighted average common stock outstanding, basic and diluted | 33,451,025 | 2,166,976 | 28,989,007 | 2,224,482 | |||||||||||
| Net loss per share, basic and diluted | $ | (0.73 | ) | $ | (4.53 | ) | $ | (2.00 | ) | $ | (12.28 | ) | |||
| Condensed Statements of Operations | |||||||
| (in thousands, except share and per share data) | |||||||
| (unaudited) | |||||||
| Assets | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 208,687 | $ | 96,358 | |||
| Short-term investments | 7,072 | 11,078 | |||||
| Other receivables | 574 | 431 | |||||
| Prepaid expenses and other current assets | 1,582 | 901 | |||||
| Total current assets | 217,915 | 108,768 | |||||
| Other non-current assets | 689 | 492 | |||||
| Property and equipment, net | 6,344 | 2,339 | |||||
| Deferred offering costs | - | 2,715 | |||||
| Right-of-use asset | 1,401 | 1,552 | |||||
| Total assets | $ | 226,349 | $ | 115,866 | |||
| Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | |||||||
| Current liabilities | |||||||
| Accounts payable | $ | 5,649 | $ | 2,696 | |||
| Payroll-related accruals | 2,508 | 2,182 | |||||
| Other current liabilities | 6,140 | 3,706 | |||||
| Total current liabilities | 14,297 | 8,584 | |||||
| Lease liability, non-current | 1,609 | 1,582 | |||||
| Total liabilities | 15,906 | 10,166 | |||||
| Commitments and contingencies | |||||||
| Redeemable convertible preferred stock, | - | 204,537 | |||||
| Stockholders' equity (deficit) | |||||||
| Preferred stock, | - | - | |||||
| Common stock, | - | - | |||||
| Common stock additional paid-in capital | 373,108 | 5,893 | |||||
| Accumulated deficit | (162,665 | ) | (104,730 | ) | |||
| Total stockholders' equity (deficit) | 210,443 | (98,837 | ) | ||||
| Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | $ | 226,349 | $ | 115,866 | |||
Source: